Nutriband Inc. (NASDAQ:NTRB) Sees Significant Decline in Short Interest

Nutriband Inc. (NASDAQ:NTRB) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 56,300 shares, a decline of 14.3% from the May 31st total of 65,700 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average trading volume of 62,000 shares, the short-interest ratio is presently 0.9 days.

Institutional Investors Weigh In On Nutriband

An institutional investor recently bought a new position in Nutriband stock. Virtu Financial LLC bought a new position in shares of Nutriband Inc. (NASDAQ:NTRB) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,862 shares of the company’s stock, valued at approximately $58,000. Virtu Financial LLC owned about 0.12% of Nutriband at the end of the most recent quarter. 19.70% of the stock is currently owned by institutional investors.

Nutriband Stock Performance

Shares of NTRB traded down $0.08 during midday trading on Tuesday, hitting $5.91. The stock had a trading volume of 29,171 shares, compared to its average volume of 36,415. The stock’s 50 day moving average is $4.74 and its 200 day moving average is $3.59. The company has a current ratio of 6.16, a quick ratio of 6.04 and a debt-to-equity ratio of 0.03. Nutriband has a 1 year low of $1.53 and a 1 year high of $6.75.

Nutriband (NASDAQ:NTRB) last posted its quarterly earnings data on Friday, May 31st. The company reported ($0.21) earnings per share for the quarter. Nutriband had a negative return on equity of 71.77% and a negative net margin of 315.56%. The firm had revenue of $0.41 million during the quarter.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.